Partner organizations

 

http://www.bioneer.dk/bioneer-logo-20040120-lille_farve_gal

Bioneer A/S is a Danish Contract Research Organization within biotechnology and biomedicine located in Hørsholm, close to Copenhagen. Bioneer A/S is a subsidiary of the Technical University of Denmark and is approved by the Danish Ministry of Higher Education and Innovation as an authorized provider of technological services.

ESR’s in the custody of Bioneer will have access to a technology platform and an infrastructure to perform RNA in situ detection, immunohistochemistry, multiplex detection, epifluorescence and bright field microscopy and whole slide scanning. ESR’s will be trained in state-of-the-art in situ hybridization (ISH) technologies for visualization of RNA-species in cytological and histological samples.

 

eurice

http://eurice.eu/

Founded in 2000, Eurice – European Research and Project Office GmbH provides comprehensive support services for the planning, initiation, and implementation of large international collaborative projects. With its strong background in Intellectual Property and Innovation Management, Eurice helps consortia in Horizon 2020 to develop and implement coherent IP management strategies and supports consortia through dissemination, networking, training, and capacity building activities.

Within circRTrain, Eurice provides IPR training and guidance as part of the network training programme. As a member of a dedicated IPR Board, Eurice will support the circRTrain network with advice on IP/IPR management, assisting in development of exploitation, business and development strategies.

 

 

exosomics_logo

http://www.exosomics.eu/

Exosomics Siena is located within Medicine Research Centre of Toscana Life Sciences BioPark in Siena. Our mission is to develop, clinically validate and commercialize exosomes based diagnostic tools that will reduce complexity, time and costs of cancer screening, monitoring and support precision medicine. Exosomics biofluid biopsy  is based on detection of  specific  metabolic markers  on  tumor-released vesicles and their selective isolation from accessible biofluids such as  blood or urine. This approach offers comprehensive advantages over conventional and emerging technologies such as cfDNA and CTCs in terms of low sample consumption, stability, reliability, sensitivity and early detection of actionable genomic alterations.

 

161021_qpa_bioanalytics_cmyk

 http://www.q-p-a.de/

qpa develops innovative biochips and devices for (clinical) analytics and diagnostics. Starting from array-based biochips to modified microtiter plates, qpa develops comprehensive assays to simplify and accelerate drug discovery and diagnostics development. The company’s mission is to combine cutting edge biological and medical research with the latest biotechnology to develop and produce novel tools for the benefit of patients. qpa serves as a partner for assay development, biological interaction analysis and microarray manufacturing within the circRTrain consortium.

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken

Merken